Cargando…

Identification of key genes in osteosarcoma – before and after CDK7 treatment

BACKGROUND: Osteosarcoma is one of the most common bone tumors, with a high degree of malignancy and a poor prognosis. Recent studies have shown that THZ2, a cyclin-dependent kinase 7 inhibitor, can exhibit strong antibone tumor effects in vivo and in vitro by inhibiting transcriptional activity. In...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Yang, Wang, Yuanlin, Xu, Guoyong, Liao, Yinan, Huang, Ge, Jin, Xin, Xie, Chengxin, Li, Qinglong, Yin, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483848/
https://www.ncbi.nlm.nih.gov/pubmed/34596127
http://dx.doi.org/10.1097/MD.0000000000027304
_version_ 1784577200659365888
author An, Yang
Wang, Yuanlin
Xu, Guoyong
Liao, Yinan
Huang, Ge
Jin, Xin
Xie, Chengxin
Li, Qinglong
Yin, Dong
author_facet An, Yang
Wang, Yuanlin
Xu, Guoyong
Liao, Yinan
Huang, Ge
Jin, Xin
Xie, Chengxin
Li, Qinglong
Yin, Dong
author_sort An, Yang
collection PubMed
description BACKGROUND: Osteosarcoma is one of the most common bone tumors, with a high degree of malignancy and a poor prognosis. Recent studies have shown that THZ2, a cyclin-dependent kinase 7 inhibitor, can exhibit strong antibone tumor effects in vivo and in vitro by inhibiting transcriptional activity. In this study, by screening the differentially expressed genes (DEGs) of osteosarcoma cells before and after THZ2 treatment, it provides new possible targets for the future targeted therapy of osteosarcoma. METHODS: Download the gene expression profile of GSE134603 from the Gene Expression Omnibus database, and use the R software package “limma Geoquery” to screen DEGs. DAVID database was used for gene ontology analysis of DEGs. Use search tool for the retrieval of interacting genes online database and Cytoscape software to construct protein–protein interaction network. Use the “MCODE” plugin in Cytoscape to analyze key molecular complexes (module) of DEGs, and use the “Cluego” plugin to perform Kyoto Encyclopedia of Genes and Genomes enrichment analysis on module genes. The Hub gene is selected from the genes in DEGs that coexist in the top 30 Degree and the Kyoto Encyclopedia of Genes and Genomes pathway. RESULTS: A total of 1033 DEGs were screened, including 800 up-regulated genes and 233 down-regulated genes. Gene ontology analysis showed that cell component is the main enrichment area of DEGs, mainly in the nucleus, cytoplasm, and nucleoplasm. In addition, in molecular function analysis, DEGs are mainly enriched in the process of protein binding. In biological process analysis, changes in DEGs can also be observed in transcription and regulation using DNA as a template. Twenty-nine module genes are enriched in the Ribosome biogenesis in eukaryotes pathway. Finally, 4 key genes are drawn: essential for mitotic growth 1, U3 SnoRNP protein 3 homolog, U3 small nucleolar RNA-associated protein 15 homolog, and WD repeat domain 3. CONCLUSION: This study found that the 4 genes essential for mitotic growth 1, U3 SnoRNP protein 3 homolog, U3 small nucleolar RNA-associated protein 15 homolog, WD repeat domain 3, and the ribosome biogenesis in eukaryotes pathway play a very important role in the occurrence and development of osteosarcoma, and can become a new target for molecular targeted therapy of osteosarcoma in the future.
format Online
Article
Text
id pubmed-8483848
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-84838482021-10-04 Identification of key genes in osteosarcoma – before and after CDK7 treatment An, Yang Wang, Yuanlin Xu, Guoyong Liao, Yinan Huang, Ge Jin, Xin Xie, Chengxin Li, Qinglong Yin, Dong Medicine (Baltimore) 5700 BACKGROUND: Osteosarcoma is one of the most common bone tumors, with a high degree of malignancy and a poor prognosis. Recent studies have shown that THZ2, a cyclin-dependent kinase 7 inhibitor, can exhibit strong antibone tumor effects in vivo and in vitro by inhibiting transcriptional activity. In this study, by screening the differentially expressed genes (DEGs) of osteosarcoma cells before and after THZ2 treatment, it provides new possible targets for the future targeted therapy of osteosarcoma. METHODS: Download the gene expression profile of GSE134603 from the Gene Expression Omnibus database, and use the R software package “limma Geoquery” to screen DEGs. DAVID database was used for gene ontology analysis of DEGs. Use search tool for the retrieval of interacting genes online database and Cytoscape software to construct protein–protein interaction network. Use the “MCODE” plugin in Cytoscape to analyze key molecular complexes (module) of DEGs, and use the “Cluego” plugin to perform Kyoto Encyclopedia of Genes and Genomes enrichment analysis on module genes. The Hub gene is selected from the genes in DEGs that coexist in the top 30 Degree and the Kyoto Encyclopedia of Genes and Genomes pathway. RESULTS: A total of 1033 DEGs were screened, including 800 up-regulated genes and 233 down-regulated genes. Gene ontology analysis showed that cell component is the main enrichment area of DEGs, mainly in the nucleus, cytoplasm, and nucleoplasm. In addition, in molecular function analysis, DEGs are mainly enriched in the process of protein binding. In biological process analysis, changes in DEGs can also be observed in transcription and regulation using DNA as a template. Twenty-nine module genes are enriched in the Ribosome biogenesis in eukaryotes pathway. Finally, 4 key genes are drawn: essential for mitotic growth 1, U3 SnoRNP protein 3 homolog, U3 small nucleolar RNA-associated protein 15 homolog, and WD repeat domain 3. CONCLUSION: This study found that the 4 genes essential for mitotic growth 1, U3 SnoRNP protein 3 homolog, U3 small nucleolar RNA-associated protein 15 homolog, WD repeat domain 3, and the ribosome biogenesis in eukaryotes pathway play a very important role in the occurrence and development of osteosarcoma, and can become a new target for molecular targeted therapy of osteosarcoma in the future. Lippincott Williams & Wilkins 2021-10-01 /pmc/articles/PMC8483848/ /pubmed/34596127 http://dx.doi.org/10.1097/MD.0000000000027304 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 5700
An, Yang
Wang, Yuanlin
Xu, Guoyong
Liao, Yinan
Huang, Ge
Jin, Xin
Xie, Chengxin
Li, Qinglong
Yin, Dong
Identification of key genes in osteosarcoma – before and after CDK7 treatment
title Identification of key genes in osteosarcoma – before and after CDK7 treatment
title_full Identification of key genes in osteosarcoma – before and after CDK7 treatment
title_fullStr Identification of key genes in osteosarcoma – before and after CDK7 treatment
title_full_unstemmed Identification of key genes in osteosarcoma – before and after CDK7 treatment
title_short Identification of key genes in osteosarcoma – before and after CDK7 treatment
title_sort identification of key genes in osteosarcoma – before and after cdk7 treatment
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483848/
https://www.ncbi.nlm.nih.gov/pubmed/34596127
http://dx.doi.org/10.1097/MD.0000000000027304
work_keys_str_mv AT anyang identificationofkeygenesinosteosarcomabeforeandaftercdk7treatment
AT wangyuanlin identificationofkeygenesinosteosarcomabeforeandaftercdk7treatment
AT xuguoyong identificationofkeygenesinosteosarcomabeforeandaftercdk7treatment
AT liaoyinan identificationofkeygenesinosteosarcomabeforeandaftercdk7treatment
AT huangge identificationofkeygenesinosteosarcomabeforeandaftercdk7treatment
AT jinxin identificationofkeygenesinosteosarcomabeforeandaftercdk7treatment
AT xiechengxin identificationofkeygenesinosteosarcomabeforeandaftercdk7treatment
AT liqinglong identificationofkeygenesinosteosarcomabeforeandaftercdk7treatment
AT yindong identificationofkeygenesinosteosarcomabeforeandaftercdk7treatment